Citalopram and cardiac toxicity
Authors:
- 21 September 2012
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (4) , 755-760
Abstract
Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is widely used in clinical practice. Recent data have indicated that high therapeutic citalopram doses may cause electrocardiographic abnormalities, and the regulatory authorities have amended its licenced dosage. The present manuscript reviews the available data concerning citalopram and cardiac toxicity. Published data concerning the cardiac effects of citalopram were ascertained, and clinical data were considered separately between adverse effects arising from therapeutic use versus toxicity in the setting of intentional overdose. The occurrence of electrocardiographic abnormalities has long been recognised as a complication of acute citalopram overdose; a dose-effect relationship for QT prolongation has been described in a number of large case series, including several cases of torsades de pointes. In contrast, few data indicate the occurrence of QT prolongation and arrhythmia after therapeutic doses, and a dose-effect relationship within the therapeutic range has only recently been established. Citalopram is more likely to cause QT prolongation in patients with metabolic disturbance or pre-existing cardiac disease. A dose-effect relationship for QT prolongation exists across a broad range of citalopram doses, such that caution must be exercised when prescribing high doses or if there are co-existent risk factors for QT effects. The available data illustrate how clinical toxicity data may offer an earlier signal of cardiac effects than ascertained from conventional pharmacovigilance methods.Keywords
This publication has 36 references indexed in Scilit:
- Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature reviewGeneral Hospital Psychiatry, 2012
- Drug monitoring of a case of citalopram overdosageDrug and Chemical Toxicology, 2011
- Citalopram-induced long QT syndrome and torsade de pointes: Role for concomitant therapy and diseaseInternational Journal of Cardiology, 2011
- Impact of Withdrawal of the Analgesic Co-proxamol on Nonfatal Self-Poisoning in the UKCrisis, 2011
- Evaluation of a QT nomogram for risk assessment after antidepressant overdoseBritish Journal of Clinical Pharmacology, 2010
- Variability in the quality of overdose advice in Summary of Product Characteristics (SPC) documents: gut decontamination recommendations for CNS drugsBritish Journal of Clinical Pharmacology, 2008
- Citalopram induced torsade de pointes, a rare life threatening side effectInternational Journal of Cardiology, 2008
- Drug binding to HERG channels: evidence for a ‘non‐aromatic’ binding site for fluvoxamineBritish Journal of Pharmacology, 2003
- The safety and tolerability of citalopramInternational Clinical Psychopharmacology, 1996
- Selecting the optimum therapeutic dose of serotonin reuptake inhibitorsInternational Clinical Psychopharmacology, 1995